Middle cerebral artery embolism
Conditions
Interventions
To receive local intraarterial Urokinase (infusion of 12,000U per 5min will be repeated until a total dose reaches 60,000U, two hours pass after starting infusion, or complete recanalization is achiev
Sponsors
MELT Study Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with acute ischemic stroke of less than 6 hours duration caused by angiographically proven occlusion of the middle cerebral artery (MCA, M1 or M2), National Institutes of Health Stroke Scale (NIHSS) score of at least.
Exclusion criteria
Exclusion criteria: NIHSS>22, rapid improvement, history of stroke within previous 90 days, seizures at onset, clinical presentation suggestive of subarachnoid hemorrhage, previous history or intracranial hemorrhage at any time, neoplasm, or subarachnoid hemorrhage, septic embolism, suspected lacunar stroke, surgery, biopsy of a parenchymal organ, trauma with internal injuries or lumbar puncture within 30 days, head trauma within 90 days, active or recent hemorrhage within 30 days, known hemorrhagic diathesis, known contrast sensitivity, sustained BP > 180/100, INR > 1.7, hemorrhage or major early infarction signs on CT scan.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with slight or no neurologic disability at 90 days, as defined by a modified Rankin score of 2 or less. The ratio is compared between UK and conservative group. | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients with slight or no neurologic disability at 90 days, as defined by a modified Rankin score of 1 or less. The ratio of good outcome is compared between UK and conservative group. | — |
Countries
Japan
Contacts
Public ContactTakashi Inoue
Iwate Medical University Neurosurgery
Outcome results
None listed